MetaCap

Artiva Biotherapeutics (ARTV) vs Scribe Therapeutics (SCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Scribe Therapeutics is the larger company by market cap ($228.6 million vs $186.9 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARTV-63.37%SCTX-36.37%
+104%+16%-71%
Jul 27, 20261 yearNov 20, 2026
ARTV-62.57%SCTX-38.04%
+82%+6%-69%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARTV versus SCTX key metrics
MetricARTVSCTX
Share price$3.78$12.07
Market cap$186.85M$228.58M
1-day change-1.31%-8.70%
YTD return-11.89%—
1-year return+20.77%—
EPS (TTM)$-2.85$-6.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-83.86M—
52-week high$14.53$39.60
52-week low$2.96$12.00
Distance from 52-week high-73.98%-69.52%
Analyst consensusbuystrong_buy
Avg. price target upside+448.94%+372.25%
Average volume792.26K403.27K
Shares outstanding49.43M18.94M
Employees13477
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Artiva Biotherapeutics

ARTV stock →

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

About Scribe Therapeutics

SCTX stock →

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees

ARTV vs SCTX FAQ

Which is bigger, Artiva Biotherapeutics or Scribe Therapeutics?

Scribe Therapeutics (SCTX) is larger, with a market capitalization of $228.58M compared with $186.85M for Artiva Biotherapeutics (ARTV).

Are Artiva Biotherapeutics and Scribe Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons